Follow real-time updates on Union Budget 2023Catch exclusive videos on Union Budget 2023 from CNBC-TV18
Subject Expert Committee on Friday recommended regular market authorisation to Covishield and Covaxin. SII had applied for market approval for the Covishield vaccine in December 2021 and Bharat Biotech also applied for the same a few days ago.
Drugs Controller General of India (DCGI)'s Subject Expert Committee on Friday recommended regular market authorisation for Covishield and Covaxin, official sources said.
Recommended ArticlesView All
World Cancer Day 2023: Early detection is crucial for reducing the global burden
Feb 4, 2023 IST5 Min(s) Read
World Cancer Day 2023: A way forward to better management of cancer this year!
Feb 4, 2023 IST6 Min(s) Read
Pakistan economy at alarming level as foreign reserves drop to $3.1 billion from $16.6 billion in a year
Feb 3, 2023 IST3 Min(s) Read
FM Nirmala Sitharaman speaks on inflation, taxes, GDP and more. Read the full interview here
Feb 3, 2023 IST37 Min(s) Read
Both the vaccines will be available at clinics and hospitals registered with CoWin, sources added.
The recommendations will be sent to DCGI for final approval. During last week's meeting the SEC had sought more data and information from the two companies.
Serum Institute of India (SII) had applied for market approval for the Covishield vaccine in December 2021 and Bharat Biotech also applied for the same a few days ago.
Both Covaxin and Covishield are currently authorized for emergency use only. EUA does not represent approval of a vaccine in the full statutory term but authorises the use of an unapproved product or unapproved use of an approved product in a declared state of emergency such as a pandemic.
A market authorisation label for a vaccine means it can be authorised for use without reservations or conditions.
Also Read - Covaxin booster dose capable of neutralising Omicron and Delta variants of COVID-19: Bharat Biotech
(Edited by : Aditi Gautam)
First Published: Jan 19, 2022 9:51 PM IST